[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Who are the key executives mentioned in the text from AbbVie?
### Assistant: The key executives mentioned in the text from AbbVie are:


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the role of Liz Shea in AbbVie?
### Assistant: Liz Shea is the Vice President of Investor Relations at AbbVie.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: When was the AbbVie Q1 2023 earnings call held?
### Assistant: The AbbVie Q1 2023 earnings call was held on April 27, 2023, at 9:00 a.m. ET.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What are some of the key products that drove AbbVie's first quarter total revenues?
### Assistant: Some of the key products that drove AbbVie's first quarter total revenues were Skyrizi, Rinvoq, Venclexta, and Vraylar.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How did AbbVie's aesthetics business perform in the first quarter of 2023?
### Assistant: AbbVie's aesthetics business performed positively in the first quarter of 2023.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How did AbbVie's international results compare to expectations in the first quarter?
### Assistant: AbbVie's international results exceeded expectations in the first quarter.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What were the consumer trends like in the U.S. for AbbVie in the first quarter?
### Assistant: Consumer trends in the U.S. for AbbVie stabilized in the first quarter.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How is U.S. Humira, AbbVie's biosimilar allergen, performing?
### Assistant: U.S. Humira, AbbVie's biosimilar allergen, is performing as expected with much of the impact driven by price.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What markets does AbbVie operate in?
### Assistant: AbbVie operates in markets including immunology, hematological oncology, neuroscience, and aesthetics.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What are some of the growth platforms for AbbVie?
### Assistant: Some of the growth platforms for AbbVie include immunology, hematological oncology, neuroscience, and aesthetics.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How has AbbVie's commercial execution been in terms of launching new products and expanded indications?
### Assistant: AbbVie's commercial execution in terms of launching new products and expanded indications has been outstanding, especially across Skyrizi and Rinvoq, and recently with Vraylar and MDD.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Which assets are expected to contribute significant revenue growth for AbbVie over the decade?
### Assistant: The assets expected to contribute significant revenue growth for AbbVie over the decade are Skyrizi, Rinvoq, Venclexta, and Vraylar.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the outlook for AbbVie's long-term growth?
### Assistant: The outlook for AbbVie's long-term growth is supported by the breadth and depth of its R&D pipeline.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the role of Roopal Thakkar in AbbVie?
### Assistant: Roopal Thakkar is the Senior Vice President of Development and Regulatory Affairs and Chief Medical Officer at AbbVie.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What are some of the risks and uncertainties mentioned by AbbVie?
### Assistant: Some of the risks and uncertainties mentioned by AbbVie include those related to forward-looking statements and the potential impact on actual results.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie reconcile non-GAAP financial measures with GAAP financial measures?
### Assistant: AbbVie reconciles non-GAAP financial measures with comparable GAAP financial measures in its earnings release and regulatory filings.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Where can investors find AbbVie's earnings release and regulatory filings?
### Assistant: Investors can find AbbVie's earnings release and regulatory filings on the company's website.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How did AbbVie's first quarter total revenues and adjusted earnings per share compare to expectations?
### Assistant: AbbVie's first quarter total revenues and adjusted earnings per share exceeded expectations.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the overall sentiment of Rick Gonzalez, AbbVie's Chairman and CEO, regarding the company's performance in the first quarter?
### Assistant: Rick Gonzalez, AbbVie's Chairman and CEO, is extremely pleased with the company's start to 2023 and the first quarter performance, which exceeded expectations.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie describe its portfolio and its presence in attractive markets?
### Assistant: AbbVie describes its portfolio as well-diversified with multiple growth platforms in highly attractive markets, including immunology, hematological oncology, neuroscience, and aesthetics.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the significance of AbbVie's R&D pipeline for its long-term growth?
### Assistant: The significance of AbbVie's R&D pipeline is that it supports the company's long-term growth outlook.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie plan to take questions from participants during the conference call?
### Assistant: AbbVie plans to take questions from participants during the conference call in the Q&A portion.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is AbbVie's stance on updating forward-looking statements?
### Assistant: AbbVie's stance on updating forward-looking statements is that it undertakes no obligation to update them, except as required by law.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie's performance in the first quarter align with its overall strategy?
### Assistant: AbbVie's performance in the first quarter aligns with its overall strategy of creating a well-diversified portfolio with multiple growth platforms and executing commercial launches successfully.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie expect its assets to contribute to revenue growth in the future?
### Assistant: AbbVie expects its assets, such as Skyrizi, Rinvoq, Venclexta, and Vraylar, to contribute to revenue growth in the future.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How is AbbVie managing the erosion of the U.S. biosimilar event for Humira?
### Assistant: AbbVie is managing the erosion of the U.S. biosimilar event for Humira well.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is AbbVie's growth platform demonstrating?
### Assistant: AbbVie's growth platform is demonstrating strong performance and exceeding expectations.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How did AbbVie perform in the first quarter of 2023?
### Assistant: AbbVie performed well in the first quarter of 2023.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What were AbbVie's adjusted earnings per share in the first quarter?
### Assistant: AbbVie's adjusted earnings per share in the first quarter were $2.46.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How much were AbbVie's total net revenues in the first quarter?
### Assistant: AbbVie's total net revenues in the first quarter were $12.2 billion.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How are Skyrizi and Rinvoq performing in terms of sales?
### Assistant: Skyrizi and Rinvoq are performing well in terms of sales and are on track to contribute more than $11 billion in combined sales this year.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What indications are Skyrizi and Rinvoq expected to expand into?
### Assistant: Skyrizi and Rinvoq are expected to expand into opportunities in IBD (Inflammatory Bowel Disease) later this year, including Rinvoq's anticipated U.S. approval in Crohn's disease and Skyrizi's European launch in Crohn's and its global regulatory submission in UC (Ulcerative Colitis).


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How is AbbVie performing in the neuroscience field?
### Assistant: AbbVie is performing exceptionally well in the neuroscience field, with total net revenues nearly $200 million above expectations.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What factors are AbbVie monitoring in the U.S. market for aesthetics procedures?
### Assistant: AbbVie is closely monitoring several economic indicators in the U.S. market for aesthetics procedures, including consumer confidence, personal consumption, and Google searches.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is AbbVie's outlook for aesthetics?
### Assistant: AbbVie has a positive outlook for aesthetics and is increasing its full-year outlook for the market.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie plan to increase its adjusted earnings per share guidance?
### Assistant: AbbVie plans to increase its adjusted earnings per share guidance by $0.10.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie feel about the performance of its diverse portfolio?
### Assistant: AbbVie is extremely pleased with the performance of its diverse portfolio.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How is AbbVie executing across its therapeutic portfolio?
### Assistant: AbbVie is executing well across its therapeutic portfolio.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How much revenue did Immunology deliver for AbbVie?
### Assistant: Immunology delivered approximately $5.6 billion in revenue for AbbVie.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is Skyrizi's market share in the U.S. biologic psoriasis market?
### Assistant: Skyrizi has a total prescription share of 30% in the U.S. biologic psoriasis market, making it the clear market leader.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What attributes differentiate Skyrizi from other therapies in the psoriasis market?
### Assistant: Skyrizi differentiates itself from other therapies in the psoriasis market with attributes such as rapid onset of action, nearly complete skin clearance, high durability of response, and quarterly dosing for maintenance therapy.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How is Skyrizi performing in psoriatic arthritis?
### Assistant: Skyrizi is experiencing strong momentum in psoriatic arthritis.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the in-play biologic share of Skyrizi in psoriatic arthritis?
### Assistant: Skyrizi has achieved an in-play biologic share of new and switching patients in psoriatic arthritis.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How is Vraylar sales accelerating for AbbVie?
### Assistant: Vraylar sales are accelerating for AbbVie following MDD (Major Depressive Disorder) approval.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How is the aesthetics market performing for AbbVie in China?
### Assistant: The aesthetics market is performing better than expected in China, with positive recovery trends.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What economic indicators is AbbVie monitoring for aesthetics procedures?
### Assistant: AbbVie is monitoring several economic indicators for aesthetics procedures in the U.S., including consumer confidence, personal consumption, and Google searches.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is AbbVie's full-year adjusted earnings per share guidance?
### Assistant: AbbVie's full-year adjusted earnings per share guidance is between $10.72 and $11.12.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie feel about the long-term outlook of the business?
### Assistant: AbbVie feels confident in the long-term outlook of the business.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How is AbbVie's commercial execution across its therapeutic portfolio?
### Assistant: AbbVie's commercial execution across its therapeutic portfolio is strong.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is Skyrizi's quarterly dosing schedule for maintenance therapy?
### Assistant: Skyrizi has a quarterly dosing schedule for maintenance therapy.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the market share of Skyrizi in the U.S. dermatology segment?
### Assistant: The market share of Skyrizi in the U.S. dermatology segment is roughly 20%.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How many countries has Skyrizi achieved psoriatic disease leadership in?
### Assistant: Skyrizi has achieved psoriatic disease leadership in more than 25 countries.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: In how many key markets does Skyrizi have total market share leadership?
### Assistant: Skyrizi has total market share leadership in nearly 20 key markets.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Which medication has the second highest in-play patient share in Crohn's disease after Stelara?
### Assistant: The medication with the second highest in-play patient share in Crohn's disease after Stelara is Skyrizi.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How is the feedback from gastroenterologists regarding Skyrizi's dosing and clinical profile?
### Assistant: The feedback from gastroenterologists regarding Skyrizi's dosing and clinical profile is very positive.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: In which countries are there strong upticks in the adoption of Skyrizi?
### Assistant: There are strong upticks in the adoption of Skyrizi in Japan and Canada.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What recent data was reported for Skyrizi in ulcerative colitis?
### Assistant: Recent data reported for Skyrizi in ulcerative colitis showed strong induction data.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What potential new indication does Skyrizi represent across inflammatory bowel disease?
### Assistant: Skyrizi represents a potential new indication across inflammatory bowel disease.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How much did Rinvoq's global sales amount to?
### Assistant: Rinvoq's global sales amounted to $686 million.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How much did Rinvoq's operational growth percentage increase by?
### Assistant: Rinvoq's operational growth percentage increased by more than 50%.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How is Rinvoq performing in rheumatology with regards to total prescriptions?
### Assistant: Rinvoq is performing well in rheumatology with total prescriptions increasing across each of the four approved indications.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How is Rinvoq's market share momentum globally?
### Assistant: Rinvoq's market share momentum globally is increasing, with in-play patient share reaching approximately 17% in the U.S.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the in-play patient share of Rinvoq in the U.S.?
### Assistant: The in-play patient share of Rinvoq in the U.S. is 23% in the second-line plus setting.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the growth potential of Rinvoq in gastroenterology?
### Assistant: Rinvoq has significant growth potential in gastroenterology.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How is Rinvoq performing in ulcerative colitis and Crohn's disease in terms of remission and endoscopic improvement rates?
### Assistant: Rinvoq is demonstrating strong rates of remission and endoscopic improvement in both ulcerative colitis and Crohn's disease.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is Rinvoq's in-play share in the U.S. second-line plus setting?
### Assistant: Rinvoq's in-play share in the U.S. second-line plus setting is 23%.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: In which geography is Rinvoq the only JAK approved to treat both IBD conditions?
### Assistant: Rinvoq is the only JAK approved to treat both IBD conditions in the European Union (E.U.).


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: When is Rinvoq's CD approval and commercialization in the U.S. anticipated?
### Assistant: Rinvoq's CD approval and commercialization in the U.S. is anticipated later in this quarter.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How is the erosion of Humira sales in the U.S. attributed?
### Assistant: The erosion of Humira sales in the U.S. is attributed to biosimilar competition and price impact.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What were the total revenues for Hematologic Oncology?
### Assistant: The total revenues for Hematologic Oncology were $1.4 billion.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How did Imbruvica's global revenues change and why?
### Assistant: Imbruvica's global revenues decreased by 25.2% due to increasing competition and a suppressed market.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What was the operational basis growth of Venclexta's global sales?
### Assistant: Venclexta's global sales had an operational basis growth of 17.5%.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How did Vraylar's sales perform and what was the operational basis growth?
### Assistant: Vraylar's sales performed exceptionally well with an operational basis growth of 31.3%.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the opportunity for accelerated growth across all approved indications for Vraylar?
### Assistant: There is an opportunity for accelerated growth across all approved indications for Vraylar.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Will the full-year guidance for Vraylar be raised?
### Assistant: The full-year guidance for Vraylar will be raised.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How much did AbbVie's leading oral CGRP therapies contribute to sales this quarter?
### Assistant: AbbVie's leading oral CGRP therapies contributed $218 million in combined sales this quarter.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the growth rate of AbbVie's leading oral CGRP therapies?
### Assistant: The growth rate of AbbVie's leading oral CGRP therapies is more than 45%.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Which two medications are experiencing strong prescription demand for migraine treatment?
### Assistant: The two medications experiencing strong prescription demand for migraine treatment are Ubrelvy and Qulipta.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the unique positioning of Qulipta in the migraine market?
### Assistant: Qulipta is uniquely positioned as the only oral CGRP available as a preventative treatment for patients with both chronic and episodic migraine, strengthening AbbVie's competitive profile.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How much were the total Botox Therapeutic sales for AbbVie?
### Assistant: The total Botox Therapeutic sales for AbbVie were $719 million.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How did Botox Therapeutic sales perform in the chronic migraine market?
### Assistant: Botox Therapeutic sales performed strongly in the chronic migraine market.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the role of Carrie Strom at AbbVie?
### Assistant: Carrie Strom is the Senior Vice President of AbbVie and the President of Global Allergan Aesthetics.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How did AbbVie's global aesthetic sales perform in the first quarter?
### Assistant: AbbVie's global aesthetic sales performed ahead of guidance in the first quarter, with approximately $1.3 billion in sales.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What factors contributed to the higher-than-expected global aesthetic sales in China?
### Assistant: The higher-than-expected global aesthetic sales in China were primarily due to a faster reopening in the country and a slightly stronger economy in the U.S. compared to planning assumptions.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How did the U.S. aesthetic sales compare to AbbVie's planning assumptions?
### Assistant: The U.S. aesthetic sales were down 8.1% compared to AbbVie's planning assumptions.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What was the performance of U.S. Botox cosmetic sales in the first quarter?
### Assistant: U.S. Botox cosmetic sales were $409 million, slightly down on a year-over-year basis.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How did inflationary dynamics impact the aesthetic procedures market?
### Assistant: Inflationary dynamics impacted the aesthetic procedures market, leading to softness in aesthetic procedures related to consumer spending.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the market share of Botox cosmetic in the U.S. toxin market?
### Assistant: Botox cosmetic continues to be the clear market leader with a stable share of the U.S. toxin market.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How did the U.S. filler market perform in the first quarter?
### Assistant: The U.S. filler market was down nearly 20% in the first quarter on a year-over-year basis.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How did AbbVie's Juvederm collection perform in the U.S. market?
### Assistant: AbbVie's Juvederm collection sales in the U.S. were down 18%.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the impact of inflationary pressure on consumer spending on AbbVie's dermal filler portfolio?
### Assistant: Inflationary pressure on consumer spending negatively impacted AbbVie's dermal filler portfolio.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How did the recently launched Volux filler perform in the U.S. market?
### Assistant: The recently launched Volux filler had a strong initial uptake in the U.S. market.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the upcoming launch that is expected to support long-term growth for AbbVie's filler portfolio?
### Assistant: The upcoming launch of the skin quality injectable Skin Vive is expected to support long-term growth for AbbVie's filler portfolio.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How is the aesthetics category in the U.S. being affected by the soft economy?
### Assistant: The aesthetics category in the U.S. is being affected by the soft economy, leading to challenges in the market.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How did AbbVie's international aesthetics portfolio perform?
### Assistant: AbbVie's international aesthetics portfolio demonstrated robust growth, with sales of $523 million, up 7.8% on an operational basis.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Which countries showed strong performance in AbbVie's international aesthetics portfolio?
### Assistant: Japan and China showed strong performance in AbbVie's international aesthetics portfolio.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How did international Botox cosmetic sales grow on an operational basis?
### Assistant: International Botox cosmetic sales grew approximately 17.5% on an operational basis.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How did international Juvederm sales perform on an operational basis?
### Assistant: International Juvederm sales were down approximately 1.4% on an operational basis.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How was China's market impacted by COVID in the first quarter?
### Assistant: China's market was negatively impacted by COVID in January and February but experienced a sharp recovery in March.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How is AbbVie increasing its full-year outlook for the aesthetics business based on positive trends and strong momentum?
### Assistant: AbbVie is increasing its full-year outlook for the aesthetics business based on positive trends and strong momentum in the market.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is AbbVie's projected total sales by the end of the decade?
### Assistant: AbbVie's projected total sales by the end of the decade is more than $9 billion.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie view the aesthetics market?
### Assistant: AbbVie views the aesthetics market as an extremely attractive underpenetrated market with the potential for robust growth over the long term.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Who is the Senior Vice President of Research and Development and Chief Scientific Officer at AbbVie?
### Assistant: The Senior Vice President of Research and Development and Chief Scientific Officer at AbbVie is Tom Hudson.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What recent approval did AbbVie receive for Rinvoq?
### Assistant: AbbVie recently received European approval for Rinvoq in Crohn's disease.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What disease is Rinvoq approved for?
### Assistant: Rinvoq is approved for Crohn's disease.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: When does AbbVie anticipate FDA approval for Rinvoq in Crohn's disease?
### Assistant: AbbVie anticipates FDA approval for Rinvoq in Crohn's disease next month.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What were the results of the phase 3 induction study for Skyrizi in ulcerative colitis?
### Assistant: The phase 3 induction study for Skyrizi in ulcerative colitis showed that Skyrizi met the primary and all secondary endpoints, demonstrating a strong impact on the disease as measured by clinical remission, clinical response, and endoscopic improvement.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How did Skyrizi perform compared to placebo in the induction study?
### Assistant: Skyrizi performed significantly better than placebo in the induction study, with approximately 37% of Skyrizi-treated patients achieving endoscopic improvement compared to 12% of patients on placebo.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What potential does Skyrizi have as a therapy?
### Assistant: Skyrizi has the potential to be a highly effective therapy and a welcome new treatment option for physicians and patients once approved.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: When will detailed data from the Skyrizi induction study be presented?
### Assistant: Detailed data from the Skyrizi induction study will be presented at a forthcoming medical meeting.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: When can we expect data from the phase 3 maintenance study for Skyrizi?
### Assistant: Data from the phase 3 maintenance study for Skyrizi is expected in the second quarter.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What progress has AbbVie made in their hematology and solid tumor pipelines?
### Assistant: AbbVie has made good progress across all stages of their hematology and solid tumor pipelines.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What regulatory approval is AbbVie on track for in relapsed refractory large B cell lymphoma?
### Assistant: AbbVie is on track for regulatory approval for Epcoritamab in relapsed refractory large B cell lymphoma.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What phase 3 data is expected for VENCLEXTA CANOVA trial?
### Assistant: Phase 3 data is expected for VENCLEXTA CANOVA trial in relapsed refractory multiple myeloma patients with a T11,14 mutation.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What phase 2 data is expected for Teliso-V?
### Assistant: Phase 2 data is expected for Teliso-V in second line plus advanced non-squamous non-small cell lung cancer.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What tumors will AbbVie evaluate ABBV-400 in?
### Assistant: AbbVie will evaluate ABBV-400 in earlier lines of colorectal cancer and in tumors where CMAT is expressed, including pancreatic and liver cancer.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What recent FDA approval did AbbVie receive for Qulipta?
### Assistant: AbbVie recently received FDA approval for Qulipta as a preventive treatment for patients with chronic migraine.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is Qulipta approved for?
### Assistant: Qulipta is approved for the prevention of both episodic and chronic migraine.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What were the results of the phase 3 study for Qulipta?
### Assistant: The phase 3 study for Qulipta showed that it provided a significant reduction in migraine days, as well as significant improvements in function and quality of life in patients with chronic migraine.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What approval decision does AbbVie anticipate for Atogepant in Europe?
### Assistant: AbbVie anticipates an approval decision in the third quarter for Atogepant as a preventive treatment for patients with both chronic and episodic migraine in Europe.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What additional information does the FDA request regarding ABBV-951?
### Assistant: The FDA requests additional information regarding the pump for ABBV-951.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What updates are requested for the instruction for use of ABBV-951?
### Assistant: The FDA requests updates to the instruction for use of ABBV-951.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: When does AbbVie expect to respond to the complete response letter for ABBV-951?
### Assistant: AbbVie expects to respond to the complete response letter for ABBV-951 later this year.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the purpose of ABBV-951?
### Assistant: The purpose of ABBV-951 is not mentioned in the given text.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is AbbVie's plan for the CRL response for ABBV-951?
### Assistant: AbbVie's plan for the CRL response for ABBV-951 is to generate the necessary information and provide the requested updates to the FDA.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the anticipated action by AbbVie in the first half of '24?
### Assistant: The anticipated action by AbbVie in the first half of '24 is not specified in the given text.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: In which international market has AbbVie recently received approval for 951?
### Assistant: AbbVie has recently received approval for 951 in Japan.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: When does AbbVie expect approval in Europe for 951?
### Assistant: AbbVie expects approval in Europe for 951 in the fourth quarter of this year.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the selective D3 dopamine receptor agonist being studied by AbbVie?
### Assistant: The selective D3 dopamine receptor agonist being studied by AbbVie is ABBV-932.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What potential clinical benefit does AbbVie highlight in relation to Vraylar?
### Assistant: AbbVie highlights the potential clinical benefit of achieving D3 selectivity in relation to Vraylar.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What psychiatric disorder is AbbVie's program initially focusing on?
### Assistant: AbbVie's program is initially focusing on general anxiety disorder.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How many assets in clinical trials does AbbVie have under its collaboration with Calico?
### Assistant: AbbVie has four assets in clinical trials under its collaboration with Calico.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the most advanced program in AbbVie's collaboration with Calico?
### Assistant: The most advanced program in AbbVie's collaboration with Calico is the eIF2B activator 7262.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Which organization is conducting the HEALEY ALS platform trial for AbbVie's eIF2B activator 7262?
### Assistant: The HEALEY ALS platform trial for AbbVie's eIF2B activator 7262 is conducted by the Healey Center for ALS at Mass General.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the goal of the HEALEY ALS platform trial?
### Assistant: The goal of the HEALEY ALS platform trial is to evaluate multiple therapies simultaneously with the aim of accelerating the development of potential breakthrough treatments for ALS.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What was the outcome of AbbVie's proof-of-concept study for cystic fibrosis?
### Assistant: The outcome of AbbVie's proof-of-concept study for cystic fibrosis did not meet their criteria for advancing, indicating that the results were not favorable.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Why is AbbVie discontinuing its cystic fibrosis program?
### Assistant: AbbVie is discontinuing its cystic fibrosis program because the results from the ongoing proof-of-concept study did not meet their criteria for advancing.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What were the results of AbbVie's exploratory studies for ABBV-154 in PMR and Crohn's disease?
### Assistant: The results of AbbVie's exploratory studies for ABBV-154 in PMR and Crohn's disease showed efficacy with 154, but also observed changes in biomarkers consistent with systemic steroid exposure at higher doses.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Why will AbbVie not be pursuing the development of ABBV-154?
### Assistant: AbbVie will not be pursuing the development of ABBV-154 based on the totality of the data across RA, PMR, and Crohn's disease studies, as the benefit-risk profile does not sufficiently differentiate 154 from other available treatments.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What were the results of AbbVie's phase 3 studies for Botox in platysma prominence and masseter muscle prominence?
### Assistant: The results of AbbVie's phase 3 studies for Botox in platysma prominence and masseter muscle prominence were not specified in the given text.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the focus of AbbVie's aesthetic pipeline program for Botox?
### Assistant: AbbVie's aesthetic pipeline program for Botox is initially focused on China and other Asian markets, as masseter prominence is common in Asian populations and there is a significant unmet need for minimally invasive treatment options.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: When does AbbVie expect to submit its regulatory application for Botox in China?
### Assistant: AbbVie expects to submit its regulatory application for Botox in China in the second half of the year.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Why does AbbVie anticipate high demand for Botox in China?
### Assistant: AbbVie anticipates high demand for Botox in China because there is a significant unmet need for minimally invasive treatment options for masseter prominence in Asian populations.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the expected timeline for data from the remaining phase 3 trials for Botox in platysma prominence?
### Assistant: The expected timeline for data from the remaining phase 3 trials for Botox in platysma prominence is not specified in the given text.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: When does AbbVie anticipate regulatory submission for Botox in the U.S.?
### Assistant: AbbVie anticipates regulatory submission for Botox in the U.S. near the end of 2023.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What were AbbVie's adjusted earnings per share in the first quarter?
### Assistant: AbbVie's adjusted earnings per share in the first quarter were $2.46.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What was the impact of acquired IPR&D expense on AbbVie's first quarter results?
### Assistant: The impact of acquired IPR&D expense on AbbVie's first quarter results was $0.08 unfavorable.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How much were AbbVie's total net revenues in the first quarter?
### Assistant: AbbVie's total net revenues in the first quarter were $12.2 billion.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How did AbbVie's total net revenues perform on an operational basis in the first quarter?
### Assistant: AbbVie's total net revenues performed down 8.3% on an operational basis in the first quarter, excluding a specific factor that is not mentioned in the given text.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Who will be discussing AbbVie's financial results and guidance?
### Assistant: Scott Reents, Senior Vice President and Chief Financial Officer, will be discussing AbbVie's financial results and guidance.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What was the adjusted operating margin ratio for AbbVie?
### Assistant: The adjusted operating margin ratio for AbbVie was 45% of sales.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What percentage of sales was the adjusted gross margin for AbbVie?
### Assistant: The adjusted gross margin for AbbVie was 84.2% of sales.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How much was the acquired IPR&D expense as a percentage of sales for AbbVie?
### Assistant: The acquired IPR&D expense was 1.2% of sales for AbbVie.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What was the adjusted SG&A expense as a percentage of sales for AbbVie?
### Assistant: The adjusted SG&A expense was 24.4% of sales for AbbVie.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How much was AbbVie's net interest expense?
### Assistant: AbbVie's net interest expense was $454 million.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What was the adjusted tax rate for AbbVie?
### Assistant: The adjusted tax rate for AbbVie was 13.7%.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is AbbVie's updated full-year adjusted earnings per share guidance?
### Assistant: AbbVie's updated full-year adjusted earnings per share guidance is between $10.72 and $11.12.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Does AbbVie's earnings per share guidance include an estimate for acquired IPR&D expense?
### Assistant: AbbVie's earnings per share guidance does not include an estimate for acquired IPR&D expense.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the expected net revenue for AbbVie?
### Assistant: The expected net revenue for AbbVie is approximately $52.4 billion.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the expected impact of foreign exchange on AbbVie's full-year sales growth?
### Assistant: At current rates, foreign exchange is expected to have a modest unfavorable impact on AbbVie's full-year sales growth.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How much are Vraylar sales expected to increase for AbbVie?
### Assistant: Vraylar sales are expected to increase by approximately $200 million for AbbVie.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the expected global revenue for aesthetics for AbbVie?
### Assistant: The expected global revenue for aesthetics is approximately $5.3 billion for AbbVie.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the anticipated net revenue for AbbVie in the second quarter?
### Assistant: The anticipated net revenue for AbbVie in the second quarter is approximately $13.5 billion.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the expected impact of foreign exchange on AbbVie's sales growth in the second quarter?
### Assistant: At current rates, foreign exchange is expected to have a 0.6% unfavorable impact on AbbVie's sales growth in the second quarter.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the projected adjusted operating margin ratio for AbbVie in the second quarter?
### Assistant: The projected adjusted operating margin ratio for AbbVie in the second quarter is 48.5% of sales.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the forecasted non-GAAP tax rate for AbbVie in the second quarter?
### Assistant: The forecasted non-GAAP tax rate for AbbVie in the second quarter is 15.4%.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the expected range for AbbVie's adjusted earnings per share in the second quarter?
### Assistant: The expected range for AbbVie's adjusted earnings per share in the second quarter is between $2.90 and $3.00.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How has AbbVie's performance been in the current year?
### Assistant: AbbVie's performance in the current year has been strong, with financial results ahead of expectations.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Can you provide more information about AbbVie's ALS program and when data might be available?
### Assistant: AbbVie's ALS program was mentioned, but no specific information was provided about when data might be available.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Can you quantify the amount of destocking for Skyrizi and Rinvoq in the quarter for AbbVie?
### Assistant: The text does not provide specific information about the amount of destocking for Skyrizi and Rinvoq in the quarter for AbbVie.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Are rising interest rates impacting AbbVie's working capital requirements at wholesalers?
### Assistant: The text does not mention any impact of rising interest rates on AbbVie's working capital requirements at wholesalers.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Is the destocking of inventory in the retail channel impacting AbbVie's immunology products?
### Assistant: The text mentions that there was retail inventory destocking, but it does not specify if it impacted AbbVie's immunology products.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How much impact did the retain inventory destocking have on Skyrizi and Rinvoq sales for AbbVie?
### Assistant: The retain inventory destocking had a high single-digit impact on Skyrizi and Rinvoq sales for AbbVie.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Can you provide the absolute value of the impact of destocking on Skyrizi and Rinvoq sales for AbbVie?
### Assistant: The absolute value of the impact of destocking on Skyrizi sales was around $70 million, and for Rinvoq sales, it was around $30 million for AbbVie.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What was the growth in overall U.S. demand for AbbVie in the quarter?
### Assistant: The text does not provide the exact growth percentage, but it mentions that overall U.S. demand for AbbVie was up just north of 60% in the quarter.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What were the sales performance of Skyrizi and Rinvoq last year?
### Assistant: The sales performance of Skyrizi and Rinvoq last year was strong.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How much did Skyrizi sales increase last year?
### Assistant: Skyrizi sales increased by 80% last year.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How much did Rinvoq sales increase in the U.S. last year?
### Assistant: Rinvoq sales in the U.S. increased by 40% last year.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How many new indications were approved for Rinvoq?
### Assistant: Five new indications were approved for Rinvoq.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How many new indications were approved for Skyrizi?
### Assistant: Two new indications were approved for Skyrizi.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How did the retail inventory destock affect AbbVie's performance?
### Assistant: The retail inventory destock had a partial offset on AbbVie's performance.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What was the reason for the high single-digit price decrease?
### Assistant: The high single-digit price decrease was driven by rebate increases.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does the volume growth of Skyrizi and Rinvoq contribute to the price decrease?
### Assistant: The volume growth of Skyrizi and Rinvoq contributed to the price decrease.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Did the street fully appreciate the impact of the new indications on AbbVie's first quarter estimates?
### Assistant: The street may not have fully appreciated the impact of the new indications on AbbVie's first quarter estimates.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: When is AbbVie expecting to release ALS treatment?
### Assistant: AbbVie is expecting to release the ALS treatment in late 2024 or early 2025.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How long did it take to recruit patients for the ALS study?
### Assistant: It took about two years to recruit patients for the ALS study.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: When is AbbVie expecting to have results for the ALS study?
### Assistant: AbbVie is expecting to have results for the ALS study in late 2024 or early 2025, depending on enrollment.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How is AbbVie managing copay programs for Skyrizi and Rinvoq?
### Assistant: AbbVie is managing copay programs for Skyrizi and Rinvoq tightly.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Are copay resets affecting Skyrizi and Rinvoq sales?
### Assistant: Copay resets are not affecting Skyrizi and Rinvoq sales significantly.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie's copay management differ from its peers?
### Assistant: AbbVie's copay management is stable and not experiencing significant pressure compared to its peers.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Why is AbbVie's EPS guidance range wide?
### Assistant: The EPS guidance range is wide due to the dynamics of U.S. Humira.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What factors would lead to hitting the high end of the EPS guidance range?
### Assistant: Factors that would lead to hitting the high end of the EPS guidance range include positive U.S. Humira dynamics and successful management of biosimilars.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What factors would lead to hitting the low end of the EPS guidance range?
### Assistant: Factors that would lead to hitting the low end of the EPS guidance range include negative U.S. Humira dynamics and challenges in managing biosimilars.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does the U.S. Humira dynamics impact AbbVie's EPS range?
### Assistant: The U.S. Humira dynamics have a significant impact on AbbVie's EPS range.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How will the biosimilars entering the market affect AbbVie's EPS range?
### Assistant: The biosimilars entering the market will provide more clarity on the EPS range in the second quarter.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Is the high single-digit price erosion expected to continue throughout the year?
### Assistant: It is unclear if the high single-digit price erosion will continue throughout the year.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Is the price erosion a one-time issue or a long-term concern?
### Assistant: The price erosion is currently seen as a one-time issue due to the new indications and volume growth.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How do the new indications for Skyrizi and Rinvoq impact price erosion?
### Assistant: The new indications for Skyrizi and Rinvoq may contribute to the price erosion.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie manage price erosion for Skyrizi and Rinvoq?
### Assistant: AbbVie manages price erosion for Skyrizi and Rinvoq by tightly managing copay programs and rebate increases.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie plan to address the potential impact of biosimilars on Skyrizi and Rinvoq sales?
### Assistant: AbbVie plans to address the potential impact of biosimilars on Skyrizi and Rinvoq sales by closely monitoring the market and adjusting strategies accordingly.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the projected price decline for Skyrizi and Rinvoq in 2023?
### Assistant: The projected price decline for Skyrizi and Rinvoq in 2023 is expected to be down high single digits.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie expect the rate of price decline to change over time?
### Assistant: AbbVie expects the rate of price decline to moderate over time, as the initial decline was driven by the launch of new indications.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What were the key assumptions for AbbVie's 2023 planning in the aesthetics market?
### Assistant: The key assumptions for AbbVie's 2023 planning in the aesthetics market were the recovery of the U.S. economy and the recovery of the aesthetics market in China.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie track metrics related to the U.S. economy for their aesthetics business?
### Assistant: AbbVie tracks metrics related to the U.S. economy for their aesthetics business, including real personal consumption expenditure and Google.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What were the favorability trends seen in the U.S. economy for AbbVie's aesthetics business in Q1?
### Assistant: In Q1, AbbVie saw favorability in the U.S. economy for their aesthetics business, particularly in January and February.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What signs of potential softening were observed in the U.S. economy for AbbVie's aesthetics business in March?
### Assistant: In March, there were potential signs of softening in the U.S. economy for AbbVie's aesthetics business.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie expect the U.S. aesthetics market to grow for the full year?
### Assistant: AbbVie expects the U.S. aesthetics market to be down low-to-mid single digits until they lap the 2022 downturn, and then they expect flat market growth for the rest of the year.